Following the August 2024 decision by the FDA to expand the approval of dostarlimab-gxly (Jemperli) plus chemotherapy to include the frontline treatment of patients with primary advanced or recurrent endometrial cancer, patients now have greater choi... [10747 chars].. reed more
